Enric Domingo, Caroline Kelly, Jennifer Hay, Owen Sansom, Noori Maka, Karin Oien, Tim Iveson, Mark Saunders, Rachel Kerr, Ian Tomlinson, Joanne Edwards, Andrea Harkin, Marta Nowak, Viktor Koelzer, Alistair Easton, Ioannis Boukovinas, Eleni Moustou, Ippokratis Messaritakis, Maria Chondrozoumaki, Michaela Karagianni, Franck Pagès, Fanny Arnoux, Christelle Lautard, Yoann Lovera, Isabelle Boquet, Aurélie Catteau, Jérôme Galon, Ioannis Souglakos, David N Church
PURPOSE: Immunoscore (IS) is prognostic in stage III colorectal cancer (CRC) and may predict benefit of duration (6 v 3 months) of adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. We sought to determine IS prognostic and predictive value in stage-III CRC treated with adjuvant FOLFOX or oral capecitabine and infusional oxaliplatin (CAPOX) in the SCOT and IDEA-HORG trials. METHODS: Three thousand sixty-one cases had tumor samples, of which 2,643 (1,792 CAPOX) were eligible for IS testing...
March 14, 2024: Journal of Clinical Oncology